Topic

Articles

Benjamin McLeod, Technical Lead, Virica Biotech, speaks about fundamental constriction points in emerging therapies, high-titre vector-producing cells.


Drug Digest Editorial Interview Series: Fundamental Constriction Points in Emerging Therapies, High-Titre Vector-Producing Cells: Part 3

Dr. Vibha Jawa, Executive Director, Head of Biotherapeutics Bioanalysis in Nonclinical Disposition and Bioanalysis (NDB) Organization, Bristol
Myers Squibb, speaks about fundamental constriction points in emerging therapies, high-titre vector-producing cells.

Drug Digest Editorial Interview Series: Fundamental Constriction Points in Emerging Therapies, High-Titre Vector-Producing Cells: Part 2

Dr. Nicole Faust, General Manager, Cell Line Development at Cytiva, speaks about fundamental constriction points in emerging therapies, high-titre vector-producing cells.

Drug Digest Editorial Interview Series: Fundamental Constriction Points in Emerging Therapies, High-Titre Vector-Producing Cells: Part 1

The MAA is supported by data from the pivotal Phase III GEMSTONE-302 trial that evaluated treatment with sugemalimab in combination with chemotherapy in patients with metastatic NSCLC. 



Marketing Authorization Application Accepted for Sugemalimab in Metastatic Non-small Cell Lung Cancer

The European Commission has granted conditional marketing authorization to the Janssen Pharmaceutical Companies of Johnson & Johnson for CARVYKTI (ciltacabtagene autoleucel), a cell therapy for treating multiple myeloma.

J&J Receives EC Conditional Approval for its First Cell Therapy Product for Multiple Myeloma

Feliza Mirasol is the science editor for 

Further development of nucleic acid-based therapeutics has been accelerated by the recent success of mRNA vaccines.

Shining a Spotlight on Nucleic Acid-Based Therapeutics

The recent success of mRNA vaccines has opened the door for further and future development of nucleic acid-based therapies.

Nucleic Acid-based Therapeutics Are Stepping into the Spotlight

ImmunoGen and Eli Lilly and Company have entered into an agreement that gives Lilly exclusive rights to research, develop, and commercialize ADCs designed for targets selected by Lilly from ImmunoGen’s camptothecin technology.

ImmunoGen Grants Lilly Exclusive Research, Development, and Commercialization License in $1.7+ Billion ADC Deal

Eli Lilly and Company has entered into a research and collaboration agreement with Entos Pharmaceuticals to develop new therapeutics for treating neurologic disorders.

Lilly and Entos Pharmaceuticals Partner in Research Collaboration to Develop Therapies for Multiple Neurologic Indications

Pfizer’s proposed $2.26-billion acquisition of Trillium Therapeutics will add next-generation hematology-targeted immuno-therapeutics to its oncology pipeline.

Therapeutic Specific Areas